# OOVA

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oova

- Industry: Medical Devices & Equipment
- Headquarters: New York, US
- Website: www.oova.life
- Total disclosed funding: $10M
- Latest round: Series A (Aug 17, 2022)
- Investors on record: 6

## About

OOVA, Inc., based in the US, offers innovative medical solutions focusing on hormone monitoring for women's health, specifically targeting fertility and perimenopause management.Founded in 2017, OOVA, Inc. specializes in hormone monitoring solutions for women. The company's headquarters are located in New York, US. The founders, Aparna Divaraniya and Christine Becker, have previously engaged in entrepreneurial ventures. OOVA has completed a total of 4 deals with the latest funding round being a Series A, raising USD 9.060 mn led by Spero Ventures, alongside investors such as Jefferson Health, US Fertility, and Virgin. The total amount raised by the company is USD 9.060 mn, with a current valuation of USD 32.007 mn.OOVA specializes in hormone monitoring solutions primarily aimed at women navigating fertility and perimenopause. The company’s flagship products include the Fertility Hormone Kit and the Perimenopause Hormone Kit, which allow users to track levels of luteinizing hormone (LH), E3G (an estrogen metabolite), and PdG (a progesterone metabolite) through urine tests. Using a smartphone app, users can scan test strips to receive quantitative hormone reports that provide insights into cycle patterns and ovulation timing. The products are designed to empower users in managing their reproductive health, catering to various use cases such as optimizing fertility, tracking ovulation, or understanding hormonal fluctuations during perimenopause. OOVA’s offerings are accessible primarily in the United States and have garnered attention from over 100 healthcare clinics, indicating a robust client base that includes both direct consumers and healthcare providers.OOVA generates revenue primarily through direct-to-consumer sales, subscriptions, and memberships. Customers can purchase individual test kits, such as the Fertility Hormone Kit and the Perimenopause Hormone Kit, while the OOVA Membership offers a more comprehensive experience that includes access to 1:1 consultations with hormone experts and discounts on monthly test kits. The membership structure allows users to benefit from community support and expert guidance throughout their hormone tracking journey. The pricing model typically involves a one-time purchase for test kits, along with a subscription for ongoing membership services, enabling OOVA to build recurring revenue streams from engaged customers seeking continuous hormone monitoring and support.OOVA, Inc. plans to expand its product line with new hormone monitoring solutions designed for additional health needs, although specific release dates have yet to be announced. The company is also targeting expansion into international markets, with a focus on Europe and Asia by 2025. Recent funding from The Helm will support these initiatives, allowing OOVA to enhance product development and marketing efforts to reach a broader audience.

## Funding rounds

- Series A, Aug 17, 2022, $9.1M — Spero Ventures, Jefferson Health, US Fertility, Virgin
- Seed, Jul 27, 2021, $1.2M — BBG Ventures, Company Ventures

## Investors

- BBG Ventures (https://capitalatlas.ai/funds/bbg-ventures) — Seed
- Company Ventures (https://capitalatlas.ai/funds/company-ventures) — Seed
- Spero Ventures (https://capitalatlas.ai/funds/spero-ventures) — Series A
- Jefferson Health — Series A
- US Fertility — Series A
- Virgin (https://capitalatlas.ai/funds/virgin) — Series A